Publications
Detailed Information
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Andre, T. | - |
dc.contributor.author | Vernerey, D. | - |
dc.contributor.author | Im, S. A. | - |
dc.contributor.author | Bodoky, G. | - |
dc.contributor.author | Buzzoni, R. | - |
dc.contributor.author | Reingold, S. | - |
dc.contributor.author | Rivera, F. | - |
dc.contributor.author | McKendrick, J. | - |
dc.contributor.author | Scheithauer, W. | - |
dc.contributor.author | Ravit, G. | - |
dc.contributor.author | Fountzilas, G. | - |
dc.contributor.author | Yong, W. P. | - |
dc.contributor.author | Isaacs, R. | - |
dc.contributor.author | Osterlund, P. | - |
dc.contributor.author | Liang, J. T. | - |
dc.contributor.author | Creemers, G. J. | - |
dc.contributor.author | Rakez, M. | - |
dc.contributor.author | Van Cutsem, E. | - |
dc.contributor.author | Cunningham, D. | - |
dc.contributor.author | Tabernero, J. | - |
dc.contributor.author | de Gramont, A. | - |
dc.date.accessioned | 2022-03-22T09:25:08Z | - |
dc.date.available | 2022-03-22T09:25:08Z | - |
dc.date.created | 2020-05-15 | - |
dc.date.created | 2020-05-15 | - |
dc.date.created | 2020-05-15 | - |
dc.date.created | 2020-05-15 | - |
dc.date.issued | 2020-02 | - |
dc.identifier.citation | Annals of Oncology, Vol.31 No.2, pp.246-256 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.other | 100117 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177350 | - |
dc.description.abstract | Background: The bevacizumab-Avastin (R) adjuVANT (AVANT) study did not meet its primary end point of improving disease-free survival (DFS) with the addition of bevacizumab to oxaliplatin-based chemotherapy in stage III colon cancer (CC). We report here the long-term survival results (S-AVANT). Patients and methods: Patients with curatively resected stage III CC were randomly assigned to FOLFOX4, FOLFOX4-bevacizumab, or XELOX-bevacizumab. Results: A total of 2867 patients were randomized: FOLFOX4: n = 955, FOLFOX4-bevacizumab: n = 960, XELOX-bevacizumab: n = 952. With a median of 6.73 years follow-up (interquartile range 5.51-10.54), 672 patients died, of whom 198 (20.7%), 250 (26.0%), and 224 (23.5%) were in the FOLFOX4, FOLFOX4-bevacizumab, and XELOX-bevacizumab arms, respectively. The 10-year overall survival (OS) rates were 74.6%, 67.2%, and 69.9%, (P = 0.003) and 5-year disease-free survival (DFS) rates were 73.2%, 68.5%, and 71.0% (P = 0.174), respectively. OS and DFS hazard ratios were 1.29 [95% confidence interval (CI) 1.07-1.55; P = 0.008] and 1.16 (95% CI 0.99-1.37; P = 0.063) for FOLFOX4-bevacizumab versus FOLFOX4 and 1.15 (95% CI 0.95-1.39; P = 0.147) and 1.1 (95% CI 0.93 -1.29; P = 0.269) for XELOX-bevacizumab versus FOLFOX4, respectively. CC-related deaths (n = 542) occurred in 157 (79.3%) patients receiving FOLFOX4, 205 (82.0%) receiving FOLFOX4-bevacizumab, and 180 (80.4%) receiving XELOX-bevacizumab (P = 0.764), while non-CC-related deaths occurred in 41 (20.7%), 45 (18.0%), and 44 (19.6%) patients, respectively. Cardiovascular-related and sudden deaths during treatment or follow-up were reported in 13 (6.6%), 17 (6.8%), and 14 (6.3%) patients, in the FOLFOX4, FOLFOX4-bevacizuamb, and XELOX-bevacizumab arms, respectively (P = 0.789). Treatment arm, sex, age, histological differentiation, performance status, T/N stages, and localization of primary tumor were independent prognostic factors of OS in stage III. Conclusions: S-AVANT confirms the initial AVANT report. No benefit of the bevacizumab addition to FOLFOX4 adjuvant therapy in patients with stage III CC was observed in terms of DFS with a negative effect in OS, without increase in non-CC related deaths. | - |
dc.language | 영어 | - |
dc.publisher | Oxford University Press | - |
dc.title | Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1016/j.annonc.2019.12.006 | - |
dc.citation.journaltitle | Annals of Oncology | - |
dc.identifier.wosid | 000516712400012 | - |
dc.identifier.scopusid | 2-s2.0-85078554434 | - |
dc.citation.endpage | 256 | - |
dc.citation.number | 2 | - |
dc.citation.startpage | 246 | - |
dc.citation.volume | 31 | - |
dc.identifier.sci | 000516712400012 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, S. A. | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | STAGE-II | - |
dc.subject.keywordPlus | OXALIPLATIN | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordPlus | LEUCOVORIN | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | CAPECITABINE | - |
dc.subject.keywordPlus | IRINOTECAN | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordAuthor | adjuvant | - |
dc.subject.keywordAuthor | bevacizumab | - |
dc.subject.keywordAuthor | colon cancer | - |
dc.subject.keywordAuthor | FOLFOX | - |
dc.subject.keywordAuthor | XELOX | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.